Review study on use of Galvus and Galvus/Met medicines

A drug utilization review of Galvus (vildagliptin) and GalvusMet (vildagliptin plus metformin fixed-drug combination) in type 2 diabetes mellitus - DUR

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2016/06/006991

Enrollment

800

Registered

2016-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diagnosed with Type II diabetes mellitus

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult (>= 18 years) T2DM patients of both genders, who have been prescribed vildagliptin or vildagliptin-metformin fixed-dose combination (Galvus or GalvusMet). 2.Written informed consent will be obtained from patients for use of their data in hospital database for the purpose of research

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To assess the utilization of vildagliptin-metformin FDC in real-world scenario. Timepoint: Data would be collected from hospital medical records of patients with type 2 diabetes mellitus, who have been prescribed vildagliptin or its combination as per the discretion of the physician, during the study period (June 2016 - June 2017)	—

Secondary

Measure	Time frame
To assess the utilization pattern of vildagliptin and its combinations in real-world scenario.Timepoint: Data would be collected from hospital medical records of patients with type 2 diabetes mellitus, who have been prescribed vildagliptin or its combination as per the discretion of the physician, during the study period (June 2016 - June 2017)	—

Countries

India

Contacts

Public ContactDr Smit Shah

Novartis Healthcare Private Limited

smit.shah@novartis.com912224958863

Outcome results